HBV

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023
Avalon, Modified vaccinia Ankara, Autoimmunity, American Association for Cancer Research, Hepatology, Vaccine, Liver, Immunogenicity, LDN, PD-1, University, CHB, Research, Barinthus, Immune system, COVID-19, Efficacy, MVA, Hepatitis, Repeat, Hepatitis B, Infection, Cancer, HBsAg, Patient, Asian Liver Center, HBV, AASLD, Pharmaceutical industry, Oxford–AstraZeneca COVID-19 vaccine, Safety

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Retrieved on: 
Thursday, November 2, 2023
University, FDA, Human papillomavirus infection, Emergency Use Authorization, Cervical cancer, NYSE, Food, Infection, SARS-CoV-2, Physician, HPV, Pathology, Genotype, STI, PCR, Health, Hepatitis B, Aline Betancourt, CDC, HIV, Risk, HCV, Cancer, Risk assessment, HR, HIV-1, CMV, Woman, Hepatitis, EBV, Patient, Food and Drug Administration, HBV, Vaccine, Cytomegalovirus

There are many different strains of HPV, each with a unique genetic signature or genotype.

Key Points: 
  • There are many different strains of HPV, each with a unique genetic signature or genotype.
  • However, some commonly used HPV tests are not approved for primary screening and only deliver limited information regarding which of the many different genotypes of HPV are present.
  • The Alinity m high risk (HR) HPV assay is approved as a test for HPV detection and for use in routine cervical cancer screening as per professional medical guidelines.
  • "The Alinity m HR HPV assay was carefully designed to support patient care and streamline HPV testing."

Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection

Retrieved on: 
Thursday, October 26, 2023
Science, Ocean Biomedical, Research, Hepatitis, Therapy, Patient, HBV, Pharmaceutical industry, Virus

VRON-0200, a first-in-class treatment, using one of Virion’s proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient’s own immune response.

Key Points: 
  • VRON-0200, a first-in-class treatment, using one of Virion’s proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient’s own immune response.
  • This novel mechanism of action may help overcome one of the key problems faced in treating chronic HBV—immune exhaustion.
  • The international, first-in-human VRON-0200 Phase 1b study is currently enrolling patients in Hong Kong and New Zealand, with additional sites planned in the United States.
  • “We are thrilled to be partnering with Virion as they advance this important science into its clinical testing phase.

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection

Retrieved on: 
Thursday, October 26, 2023
Ocean Biomedical, Joint venture, Hepatitis, Therapy, Patient, HBV, Vaccine, Pharmaceutical industry, Virus

PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection.

Key Points: 
  • PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc. (NASDAQ: OCEA ), today announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection.
  • VRON-0200, a first-in-class treatment, using one of Virion's proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient's own immune response.
  • This novel mechanism of action may help overcome one of the key problems faced in treating chronic HBV - immune exhaustion.
  • The international, first-in-human VRON-0200 Phase 1b study is currently enrolling patients in Hong Kong and New Zealand, with additional sites planned in the United States.

Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference

Retrieved on: 
Wednesday, October 18, 2023
Arbutus, HBV, Virology, DOM events, Conference, Webcast, Therapy, Viral, Vaccine

WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:

Key Points: 
  • WARMINSTER, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference:
    H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference: Formal Presentation on October 25, 2023 at 4:30 pm ET
    To access the live webcast of the presentation please visit: https://investor.arbutusbio.com/events-presentations .
  • An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

Retrieved on: 
Wednesday, October 18, 2023
Hepatocyte, The Mark of Gideon, Hepatitis B virus, The Journal of Infectious Diseases, Immunization, Antigen, Liver, Arenavirus, Journal, Gilead Sciences, Vaccination, Disease, Hepatitis, Safety, Infection, HBV, Vaccine, Pharmaceutical industry

The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.

Key Points: 
  • The published data highlight HB-400 as a potential component in achieving a functional cure for chronic hepatitis B.
    HB-400 is an alternating, 2-vector non-replicating arenaviral therapeutic vaccine for the treatment of chronic hepatitis B.
  • It uses the Lymphocytic Choriomeningitis Virus and Pichinde Virus as arenaviral backbones, with each expressing three highly conserved hepatitis B virus antigens.
  • HB-400 is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead Sciences, Inc.
  • “The lack of curative therapies for chronic hepatitis B infection is a significant barrier to addressing the global burden of disease,” said Joern Aldag, Chief Executive Officer at HOOKIPA.

Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference

Retrieved on: 
Monday, October 23, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, Gene editing, Precision BioSciences, Conference, HBV, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.
  • Details for the virtual fireside chat are as follows:
    The fireside chat will be available via a live webcast accessible on Precision’s website in the Investors section under Events & Presentations on October 25, 2023: https://investor.precisionbiosciences.com/events-and-presentations .
  • An archived replay will be available for approximately 30 days following the event.

Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Research, IND, Death, Disease, Therapy, Hepatitis, Person, HBV, Ocean Biomedical, Infection, JV, Patient, VIR, Pharmaceutical industry, Virus

This study will also inform and expedite the other IND-enabling activities in the JV’s pipeline, including VRON-0300, for the treatment of patients with advanced solid tumors.

Key Points: 
  • This study will also inform and expedite the other IND-enabling activities in the JV’s pipeline, including VRON-0300, for the treatment of patients with advanced solid tumors.
  • Chronic HBV remains a global health issue with a high unmet medical need as there is no cure available.
  • On October 11, 2023, Ocean acquired a 50% ownership interest in Virion Therapeutics through a joint venture that includes all current and future Virion development programs.
  • Ocean is pleased to partner with Virion in bringing this high-need, high-value treatment – aiming for a functional cure – to patients with chronic HBV around the world.”

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Retrieved on: 
Tuesday, October 17, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Hospitals, Clinical Trials, Assembly, Partnership, Virology, Multimedia, Senior, BofA Securities, Viral, HDV, EPS, Organization, Bio, HSV, Hepatitis B virus, Safety, Patient, Event, IPR, HBV, Exercise, Pharmaceutical industry

Gilead’s initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing.

Key Points: 
  • Gilead’s initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing.
  • In addition, subject to certain conditions, Gilead has agreed to purchase up to 29.9 percent of Assembly Bio’s outstanding voting stock at a premium.
  • For future new programs, Assembly Bio will also have an option to co-promote those products in the United States.
  • Management from Assembly Bio will be hosting an investor webcast today at 8:30 a.m. ET/5:30 a.m. PT to discuss the Gilead partnership.

Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference

Retrieved on: 
Thursday, October 12, 2023
PT, Vir, Conference, HBV, SAN, Pharmaceutical industry, Online shopping, Research

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m.

Key Points: 
  • SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer and Interim Head of Research, is participating in a virtual fireside Q&A at the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference on Wednesday, October 25, at 7:00 a.m. PT / 10:00 a.m.
  • ET.
  • A live webcast of the fireside chat can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.